AlphAIalphai — Financial news for AI agents
stocktitan.netAUG 181 min read$DVA

DaVita (NYSE: DVA) director now holds 5,970 shares after award

DaVita (DVA) director Adam H. Schechter received a grant of 278 shares of Common Stock on August 15, 2026, at $0.00 per share, increasing his direct holdings to 5,970 shares. The transaction was reported as a Form 4 award.

Original reporting
stocktitan.net
Published Aug 18, 2026, 10:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 11:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$DVA
Neutral
high confidence
Mentioned
$DVA
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$DVANeutralLow
01

Why it matters

The award is small and does not suggest a change in insider sentiment.

02

Market read

Routine insider award with negligible market impact.

03

What to watch

None

Relevance 4/10Novelty 4/10Timing: reported after the Aug 15, 2026 filing

Background

Form 4 filing discloses a routine director stock award.

Company-level read

Ticker impact

$DVANeutralHigh confidence
Context

Director Adam H. Schechter received a grant of 278 shares, increasing his holdings to 5,970 shares.

Expected impact

Minimal effect on DVA stock price.

Evidence & confidence

The grant is a routine compensation award of negligible size relative to market float.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Unlikely to move the stock; focus on larger catalysts.

Key entities

  • Company
    DaVita Inc.

    US-listed dialysis provider (NYSE:DVA).

  • Individual
    Adam H. Schechter

    Director of DaVita receiving the award.

Read at source← All news

Related articles

AUG 27
$DVAMedAI 8/10

Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)

Berkshire Hathaway's largest proportional holding is in DaVita (DVA), a kidney dialysis center operator, with a 45% stake. Berkshire has reduced its position from 36.1 million to 28.7 million shares since early 2025. DaVita's stock is up 56% year-to-date, with Q1 revenue of $3.4 billion and adjusted profit of $198 million. The company raised its EPS guidance to $14.10-$15.20.

fool.com2 min
AUG 8
$DVAMed

DaVita Shares Rise After TD Cowen Upgrades Stock to Buy

DaVita HealthCare Partners (NYSE:DVA) rose about 2.1% premarket after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and long-term growth. The upgrade followed DaVita’s Q2 2026 results: adjusted EPS $4.02 vs $3.92 expected, revenue about $3.55B vs estimates, while guidance stayed unchanged.

yahoo.com5 min
AUG 7
$DVAMed

Why is DaVita stock up 2% today?

DaVita HealthCare Partners (DVA) rose about 2.1% in pre-open trading after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and MOTheR trial results. The upgrade followed DaVita’s Q2 2026 beat, with adjusted EPS of $4.02 vs $3.92 and revenue of about $3.55B vs forecasts, despite flat guidance.

investing.com3 min
AUG 6
$DVAMed

DaVita Inc. Q2 2026 Earnings Call Summary

DaVita reported Q2 2026 updates on dialysis operations, citing improved patient mortality and a Medicare bundle shift that reduced reliance on OTC phosphate binders by over 50%. Revenue per treatment fell sequentially. DaVita reconfirmed 2026 adjusted operating income guidance of $2.2B and expects 2026 treatment growth at the top of 25-50 bps. FDA approval of NIPRO expanded HD dialyzers may improve supply.

yahoo.com7 min